Sofinnova Partners is a Paris-based life sciences venture capital firm with offices in London and Milan and a strong European reputation. It invests from seed through growth, including crossover strategies, across biotech, medtech, and diagnostics. The firm is one of the major institutional life sciences investors in Europe.

Its neuroscience relevance comes through therapeutic and diagnostic investments tied to neurodegenerative and related disorders. While it does not appear to run a dedicated neurotech-only thesis, it has meaningful exposure to neuroscience and the European medtech environment. It is best suited to companies operating within regulated healthcare pathways rather than speculative computing-oriented neurotechnology.

Sofinnova invests primarily in Europe, with some broader international reach. For neurotech founders, it is most relevant for life-science-heavy and clinically grounded businesses seeking European market expertise and sophisticated healthcare capital. It is a strong generalist life sciences investor with meaningful neuroscience relevance.